Prise en charge des maladies inflammatoires chroniques intestinales: Mise à jour 2021 - Université de Rennes
Article Dans Une Revue Hépato-Gastro & Oncologie Digestive Année : 2021

Management of inflammatory bowel disease: Update 2021

Prise en charge des maladies inflammatoires chroniques intestinales: Mise à jour 2021

Résumé

Background: The treatment of inflammatory bowel diseases is constantly evolving through the emergence of novel molecules and treatment goals. Implementing those progresses in daily clinical practice is necessary. Methods: Thirty-one gastroenterologists practicing in France were invited to participate in a one-day consensus meeting to update previous algorithms on management of patients with Crohn's disease and ulcerative colitis for various situations. Consensus was defined as at least 66% of experts agreeing on a response. Results: All the algorithms were previously designed assuming that patients experienced a first flare of inflammatory bowel disease and are naïve of any treatment. The consensus meeting permitted to update the previous consensus algorithms through 13 clinical situations for first, second and third-line treatment of patients with Crohn's disease and ulcerative colitis. Conclusion: The changes incorporated to the algorithms provide useful guidelines to treat patients with inflammatory bowel diseases including new molecules such as vedolizumab, ustékinumab and tofacitinib and new treatment strategies. © 2021 John Libbey Eurotext. All rights reserved.
Fichier non déposé

Dates et versions

hal-03420462 , version 1 (09-11-2021)

Identifiants

Citer

A. Amiot, G. Bouguen, G. Bonnaud, Y. Bouhnik, H. Hagège, et al.. Prise en charge des maladies inflammatoires chroniques intestinales: Mise à jour 2021. Hépato-Gastro & Oncologie Digestive, 2021, 28 (4), pp.441-477. ⟨10.1684/hpg.2021.2160⟩. ⟨hal-03420462⟩
118 Consultations
0 Téléchargements

Altmetric

Partager

More